Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels.

MLA

Tashkin, Donald P., et al. “Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels.” Journal of Allergy & Clinical Immunology, vol. 137, Feb. 2016, p. AB213. EBSCOhost, https://doi.org/10.1016/j.jaci.2015.12.1283.

APA

Tashkin, D. P., Dahl, R., Virchow, J. C., Engel, M., Moroni-Zentgraf, P., Zaremba-Pechmann, L., & Kerstjens, H. A. M. (2016). Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels. Journal of Allergy & Clinical Immunology, 137, AB213. https://doi.org/10.1016/j.jaci.2015.12.1283

Chicago

Tashkin, Donald P., Ronald Dahl, Johann Christian Virchow, Michael Engel, Petra Moroni-Zentgraf, Liliana Zaremba-Pechmann, and Huib A.M. Kerstjens. 2016. “Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels.” Journal of Allergy & Clinical Immunology 137 (February): AB213. doi:10.1016/j.jaci.2015.12.1283.